Literature DB >> 15371827

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

Thomas A Stamey1, Mitchell Caldwell, John E McNeal, Rosalie Nolley, Marci Hemenez, Joshua Downs.   

Abstract

PURPOSE: We assessed how well preoperative serum prostate specific antigen (PSA) reflects the largest cancer in consecutive untreated radical prostatectomies during the last 20 years at Stanford University.
MATERIALS AND METHODS: A total of 1,317 consecutive radical prostatectomies were divided into 4, 5-year periods between August 1983 and July 2003, and examined sequentially in 3 mm step sections by 1 pathologist. The largest cancer and 5 other histological variables in each prostate were measured. Preoperative clinical stages were tabulated for each 5-year period. Means, Pearson correlation coefficients, % change and multiple regression were used to compare selected variables.
RESULTS: Most parameters decreased linearly during the 20 years, including palpable nodules on digital rectal examination from 91% to 17%, mean age from 64 to 59 years, mean serum PSA from 25 to 8 ng/ml, and index (largest) cancer volume from 5.3 to 2.4 cc. Percent Gleason grade 4/5 of the largest cancer averaged 27% to 35% and prostate weight 44 to 53 gm. Contrasting August 1983 to December 1988 with January 1999 to July 2003, 6 histological cancer parameters had statistically significant relationships to serum PSA in the first period. In the last 5 years serum PSA was related only to prostate size.
CONCLUSIONS: Serum PSA was related to prostate cancer 20 years ago. In the last 5 years serum PSA has only been related to benign prostatic hyperplasia. There is an urgent need for serum markers that reflect the size and grade of this ubiquitous cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371827     DOI: 10.1097/01.ju.0000139993.51181.5d

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  119 in total

Review 1.  Serum markers in prostate cancer detection.

Authors:  Ola Bratt; Hans Lilja
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

2.  Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.

Authors:  Bruce J Trock; Michelle J Brotzman; Leslie A Mangold; Joseph W Bigley; Jonathan I Epstein; David McLeod; Eric A Klein; J Stephen Jones; Songbai Wang; Theresa McAskill; Jyoti Mehrotra; Bhargavi Raghavan; Alan W Partin
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

Review 3.  Prostate cancer detection strategies.

Authors:  Timothy C Brand; Javier Hernandez; Edith D Canby-Hagino; Joseph W Basler; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 3.092

4.  Brief report: physicians and their personal prostate cancer-screening practices with prostate-specific antigen. A national survey.

Authors:  Evelyn C Y Chan; Michael J Barry; Sally W Vernon; Chul Ahn
Journal:  J Gen Intern Med       Date:  2006-03       Impact factor: 5.128

5.  "Prostate cancer proteomics" database.

Authors:  S S Shishkin; L I Kovalyov; M A Kovalyova; K V Lisitskaya; L S Eremina; A V Ivanov; E V Gerasimov; E G Sadykhov; N Y Ulasova; O S Sokolova; I Y Toropygin; V O Popov
Journal:  Acta Naturae       Date:  2010-10       Impact factor: 1.845

6.  Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer.

Authors:  Denong Wang; Laila Dafik; Rosalie Nolley; Wei Huang; Russell D Wolfinger; Lai-Xi Wang; Donna M Peehl
Journal:  Drug Dev Res       Date:  2013-03       Impact factor: 4.360

7.  [PSA 2010--the beginning of a new era in early detection of prostate cancer].

Authors:  C Börgermann; M Sieverding; P Fornara; M Graefen; P Hammerer; A Semjonow; F Schröder; H Rübben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

8.  Best of the 2006 AUA Annual Meeting: Highlights from the 2006 Annual Meeting of the American Urological Association, May 20-25, 2006, Atlanta, GA.

Authors: 
Journal:  Rev Urol       Date:  2006

Review 9.  Contemporary issues in the diagnosis of prostate cancer for the radiologist.

Authors:  Richard Clements
Journal:  Eur Radiol       Date:  2006-04-01       Impact factor: 5.315

Review 10.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.